Abstract: Methods and apparatuses for determining the condition of a pneumatic system air dryer are provided. An output of the pneumatic valve or of a conduit interconnected to the outlet of the pneumatic valve is positioned such that a discharge passed through the pneumatic valve while the valve is open is in view of an operator and/or is directed to a moisture sensor. Moreover, the discharge and/or an output device interconnected to the moisture sensor is in view of the operator while the operator is in a position to operate the pneumatic valve. An observation volume with a sight glass or window and/or a moisture sensor can be provided to facilitate the observation or detection of moisture or oil in the discharge.

Abstract: The present invention relates to a functional assay for I?B kinase (IKK), the proteasome and ubiquitin ligase. Cells expressing an I?B-beta-lactamase fusion protein are used to screen for inhibitors of IKK, the proteasome and ubiquitin ligase. Inhibitors identified through the inventive assay are useful in the treatment of NF-?B disorders, such as immune and inflammatory disorders. The present invention also includes cell lines useful in assays of the invention, compounds identified by assays of the invention, compositions including such compounds and methods for the treatment of disease states.

Abstract: The present invention relates to modulators of P2Y10. Various modulators are disclosed, including an antibody that binds specifically to P2Y10. The present invention also relates to methods of activating resting T lymphocytes and inhibiting the proliferation of activated T lymphocytes. Methods of upregulating trascription of P2Y10 mRNA in a resting T lymphocyte, methods of inducing expression of P2Y10 on the surface of a resting T lymphocyte and methods of activating a T lymphocyte are disclosed. Also disclosed are pharmaceuticals and methods of treating an immune disease.

Abstract: The present invention describes methods of preventing and treating inflammatory and immune-related diseases or disorders using inhibitors of I?B kinase (IKK). Also described are IKK inhibitors effective for the prevention and treatment of inflammatory and immune-related diseases or disorders, as demonstrated in vivo. Further embodiments of the present invention relate to a specific IKK inhibitors, 4(2?-aminoethyl)amino-1,8-dimethylimidazo(1,2-a) quinoxaline and compounds of formula (I), salts thereof, and pharmaceutical compositions.

Abstract: The present invention relates to modulators of P2Y10. Various modulators are disclosed, including an antibody that binds specifically to P2Y10. The present invention also relates to methods of activating resting T lymphocytes and inhibiting the proliferation of activated T lymphocytes. Methods of upregulating trascription of P2Y10 mRNA in a resting T lymphocyte, methods of inducing expression of P2Y10 on the surface of a resting T lymphocyte and methods of activating a T lymphocyte are disclosed. Also disclosed are pharmaceuticals and methods of treating an immune disease.

Abstract: Compounds that selectively bind to expanded polyglutamine repeats are disclosed. Such compounds are characterized in that they bind to a first polyglutamine peptide consisting of 60 glutamine residues under conditions in which they do not bind to a second polyglutamine peptide consisting of 20 glutamine residues. Conjugates of such compounds, nucleic acids encoding the same, and methods of use thereof are also disclosed.

Abstract: Compounds that selectively bind to expanded polyglutamine repeats are disclosed. Such compounds are characterized in that they bind to a first polyglutamine peptide consisting of 60 glutamine residues under conditions in which they do not bind to a second polyglutamine peptide consisting of 20 glutamine residues. Conjugates of such compounds, nucleic acids encoding the same, and methods of use thereof are also disclosed.

Abstract: The present invention describes methods of preventing and treating inflammatory and immune-related diseases or disorders using inhibitors of I&kgr;B kinase (IKK). Also described are IKK inhibitors effective for the prevention and treatment of inflammatory and immune-related diseases or disorders, as demonstrated in vivo. Further embodiments of the present invention relate to a specific IKK inhibitors, 4(2′-aminoethyl)amino-1,8-dimethylimidazo(1,2-a) quinoxaline and compounds of formula (I), salts thereof, and pharmaceutical compositions.

Abstract: Selective inhibitors of the cPLA2 enzymes are provided which are of use in controlling a wide variety of inflammatory diseases. The inhibitors of the present invention have the general formula where (R′), p, D, Y, Z, Ra, Rb and A are as defined in the specification.

Abstract: Compounds that selectively bind to expanded polyglutamine repeats are disclosed. Such compounds are characterized in that they bind to a first polyglutamine peptide consisting of 60 glutamine residues under conditions in which they do not bind to a second polyglutamine peptide consisting of 20 glutamine residues. Conjugates of such compounds, nucleic acids encoding the same, and methods of use thereof are also disclosed.

Abstract: Selective inhibitors of the cPLA2 enzymes are provided which are of use in controlling a wide variety of inflammatory diseases.

Abstract: GAPDH binds to expanded polyglutamine regions which are found in proteins encoded by genes with CAG repeat domains, which genes cause inherited neurodegenerative disorders and are associated with certain psychiatric disorders. Therapeutic methods are based on inhibiting the binding of GAPDH to expanded polyglutamine regions. A method of screening compounds for the ability to inhibit binding of GAPDH to polyglutamine regions is described.

Abstract: An ion mobility detector is disclosed having a drift tube of non-electrically conductive material and a series of spaced conductive rings disposed upon the exterior surface of the tube. An adjustable high voltage source is provided to apply voltages to the rings to establish a potential gradient along the drift tube. The detector further includes a reaction region separated from the drift tube by an injection gate. The ratio of the width of the conductive rings to their thickness is at least 2.1 and the ratio of the internal diameter of the drift tube to the maximum transverse dimension of the injection gate also is at least 2:1.

Abstract: A distributed feedback optical device using a single crystal boule prepared with periodic spatial striations of ternary Pb.sub.1-x Sn.sub.x Te and Yb impurity atoms forming a layered array of planar p-n junctions normal to the axis of light emission. Crystal surfaces parallel to the axis are coated with a reflective, electrical insulator. Free scattering losses are minimized by applying a magnetic field along the longitudinal axis.